Lantheus Holdings Inc

LNTH remains in Stage 2 advancing regime with a bullish medium-term bias. Price is pulling back into the rising 9/21/50 EMA support zone, offering a timely entry opportunity. Execution is recommended now on pullbacks into this support area. Key risks include overbought conditions near recent highs and failure to hold the EMAs, which would invalidate the bullish outlook.

• ↑Alzheimer’s diagnostic market projected >$1.5B by 2030 drives MK6240 uptake.
• ↑FDA approval for new F-18 PSMA PET agent expected, with 2027 revenue ramp.
• ↓Polarify revenues expected to decline 8–10% in 2026 amid pricing pressure.